155 related articles for article (PubMed ID: 11390004)
21. Trade-off between benefits, harms and economic efficiency of low-dose CT lung cancer screening: a microsimulation analysis of nodule management strategies in a population-based setting.
Treskova M; Aumann I; Golpon H; Vogel-Claussen J; Welte T; Kuhlmann A
BMC Med; 2017 Aug; 15(1):162. PubMed ID: 28838313
[TBL] [Abstract][Full Text] [Related]
22. Screening for lung cancer with CT: a preliminary cost-effectiveness analysis.
Chirikos TN; Hazelton T; Tockman M; Clark R
Chest; 2002 May; 121(5):1507-14. PubMed ID: 12006436
[TBL] [Abstract][Full Text] [Related]
23. Current estimate of costs of lung cancer screening in the United States.
Mauchley DC; Mitchell JD
Thorac Surg Clin; 2015 May; 25(2):205-15. PubMed ID: 25901564
[TBL] [Abstract][Full Text] [Related]
24. Cost-Effectiveness Analyses of Lung Cancer Screening Strategies Using Low-Dose Computed Tomography: a Systematic Review.
Raymakers AJN; Mayo J; Lam S; FitzGerald JM; Whitehurst DGT; Lynd LD
Appl Health Econ Health Policy; 2016 Aug; 14(4):409-418. PubMed ID: 26873091
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of screening for colorectal cancer in the general population.
Frazier AL; Colditz GA; Fuchs CS; Kuntz KM
JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892
[TBL] [Abstract][Full Text] [Related]
26. Shall We Screen Lung Cancer With Low-Dose Computed Tomography? Cost-Effectiveness in Hungary.
Nagy B; Szilberhorn L; Győrbíró DM; Moizs M; Bajzik G; Kerpel-Fronius A; Vokó Z
Value Health Reg Issues; 2023 Mar; 34():55-64. PubMed ID: 36502786
[TBL] [Abstract][Full Text] [Related]
27. Analysis models to assess cost effectiveness of the four strategies for the work-up of solitary pulmonary nodules.
Tsushima Y; Endo K
Med Sci Monit; 2004 May; 10(5):MT65-72. PubMed ID: 15114278
[TBL] [Abstract][Full Text] [Related]
28. Direct and indirect healthcare costs of lung cancer CT screening in Denmark: a registry study.
Jensen MD; Siersma V; Rasmussen JF; Brodersen J
BMJ Open; 2020 Jan; 10(1):e031768. PubMed ID: 31969362
[TBL] [Abstract][Full Text] [Related]
29. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of whole-body CT screening.
Beinfeld MT; Wittenberg E; Gazelle GS
Radiology; 2005 Feb; 234(2):415-22. PubMed ID: 15670999
[TBL] [Abstract][Full Text] [Related]
32. Computed tomography screening for lung cancer in the National Lung Screening Trial: a cost-effectiveness analysis.
Black WC
J Thorac Imaging; 2015 Mar; 30(2):79-87. PubMed ID: 25635704
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of a quality-controlled mammography screening program from the Swiss statutory health-care perspective: quantitative assessment of the most influential factors.
Neeser K; Szucs T; Bulliard JL; Bachmann G; Schramm W
Value Health; 2007; 10(1):42-53. PubMed ID: 17261115
[TBL] [Abstract][Full Text] [Related]
34. Screening for malignant melanoma: A cost-effectiveness analysis.
Freedberg KA; Geller AC; Miller DR; Lew RA; Koh HK
J Am Acad Dermatol; 1999 Nov; 41(5 Pt 1):738-45. PubMed ID: 10534637
[TBL] [Abstract][Full Text] [Related]
35. The cost-effectiveness of fluorodeoxyglucose 18-F positron emission tomography in the N0 neck.
Hollenbeak CS; Lowe VJ; Stack BC
Cancer; 2001 Nov; 92(9):2341-8. PubMed ID: 11745289
[TBL] [Abstract][Full Text] [Related]
36. The use of CT scanning in dementia. A systematic review.
Foster GR; Scott DA; Payne S
Int J Technol Assess Health Care; 1999; 15(2):406-23. PubMed ID: 10507198
[TBL] [Abstract][Full Text] [Related]
37. Projected Clinical, Resource Use, and Fiscal Impacts of Implementing Low-Dose Computed Tomography Lung Cancer Screening in Medicare.
Roth JA; Sullivan SD; Goulart BH; Ravelo A; Sanderson JC; Ramsey SD
J Oncol Pract; 2015 Jul; 11(4):267-72. PubMed ID: 25943596
[TBL] [Abstract][Full Text] [Related]
38. Is virtual colonoscopy a cost-effective option to screen for colorectal cancer?
Sonnenberg A; Delcò F; Bauerfeind P
Am J Gastroenterol; 1999 Aug; 94(8):2268-74. PubMed ID: 10445561
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of FDG-PET for the management of solitary pulmonary nodules: a decision analysis based on cost reimbursement in Germany.
Dietlein M; Weber K; Gandjour A; Moka D; Theissen P; Lauterbach KW; Schicha H
Eur J Nucl Med; 2000 Oct; 27(10):1441-56. PubMed ID: 11083532
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of colonoscopy in screening for colorectal cancer.
Sonnenberg A; Delcò F; Inadomi JM
Ann Intern Med; 2000 Oct; 133(8):573-84. PubMed ID: 11033584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
